Filing Flows

Filing Flows › Neurocrine Biosciences (NBIX) › Who owns the stock

Who owns Neurocrine Biosciences (NBIX) stock

732 funds reported Neurocrine Biosciences (NBIX) shares in their latest 13F filings, worth $16.8B in all. The largest holder is BlackRock ($2.3B). Last quarter 417 funds added to their stakes and 263 cut them.

Largest holders of NBIX (13F)Largest holders of NBIX (13F)BlackRock$2.3BVanguard Group$1.4BDodge & COX$941MVanguard Portfolio Management LLC$838MVanguard Capital Management LLC$766MState Street$739MAQR Capital Management LLC$643MRenaissance Technologies LLC$394MGeode Capital Management, LLC$360MTwo Sigma Investments, LP$350M

Largest holders (13F)

FundSharesValueChangeQuarter
BlackRock13,711,607$2.3Bincrease2026-06-30
Vanguard Group9,700,301$1.4Bdecrease2025-12-31
Dodge & COX5,584,707$941Mincrease2026-06-30
Vanguard Portfolio Management LLC4,974,083$838Mincrease2026-06-30
Vanguard Capital Management LLC4,545,339$766Mincrease2026-06-30
State Street4,385,598$739Mincrease2026-06-30
AQR Capital Management LLC3,818,037$643Mdecrease2026-06-30
Renaissance Technologies LLC2,335,897$394Mdecrease2026-06-30
Geode Capital Management, LLC2,138,777$360Mincrease2026-06-30
Two Sigma Investments, LP2,076,260$350Mdecrease2026-06-30
Vestal Point Capital, LP1,880,000$317Mincrease2026-06-30
BNP Paribas Asset Management Holding S.A.1,494,259$252Mincrease2026-06-30
Morgan Stanley1,318,607$222Mincrease2026-06-30
RTW Investments, LP1,267,925$214Mincrease2026-06-30
Northern Trust1,259,717$212Mincrease2026-06-30

Neurocrine Biosciences' latest quarter

Neurocrine Biosciences, Q3 2026: revenue $1.1B (+41% year over year), operating margin 29.5%, net earnings $206M, operating cash flow $395M. The chart follows the revenue to costs, profit and cash.

Questions

Who owns the most NBIX stock?

By the latest 13F filings: BlackRock ($2.3B); Vanguard Group ($1.4B); Dodge & COX ($941M); Vanguard Portfolio Management LLC ($838M); Vanguard Capital Management LLC ($766M).

What is the short interest in NBIX?

6,447,491 shares were sold short at the 2026-10-15 settlement, 10.15% of the float.

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.